{"log_id": 2550753052788808341, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0, "average": 0.953475, "min": 0.953475}, "location": {"width": 25, "top": 155, "height": 24, "left": 215}, "words": "测"}, {"probability": {"variance": 1.2e-05, "average": 0.998033, "min": 0.985658}, "location": {"width": 655, "top": 197, "height": 29, "left": 256}, "words": "2)在出现重度腹泻或呕吐的患者中,必须对突破性真菌感染进行密切监测"}, {"probability": {"variance": 0, "average": 0.99947, "min": 0.99947}, "location": {"width": 28, "top": 205, "height": 28, "left": 1124}, "words": "品"}, {"probability": {"variance": 1.4e-05, "average": 0.997367, "min": 0.984766}, "location": {"width": 743, "top": 242, "height": 29, "left": 257}, "words": "3)通常应避免可导致泊沙康唑血浆浓度降低的联合用药,除非获益超过风险。如果需"}, {"probability": {"variance": 2e-05, "average": 0.997532, "min": 0.977027}, "location": {"width": 574, "top": 289, "height": 26, "left": 218}, "words": "要使用这类药物,必须对患者出现的突破性真菌感染进行密切监测"}, {"probability": {"variance": 2e-06, "average": 0.997422, "min": 0.994395}, "location": {"width": 133, "top": 371, "height": 25, "left": 258}, "words": "3、肾功能不全"}, {"probability": {"variance": 0.003696, "average": 0.977424, "min": 0.677518}, "location": {"width": 740, "top": 409, "height": 28, "left": 260}, "words": "单次服用400mg口服混悬液后,轻度(CLcr:50~80mL/min1.73m2,n=6)和中"}, {"probability": {"variance": 0.002011, "average": 0.980972, "min": 0.768134}, "location": {"width": 784, "top": 448, "height": 26, "left": 218}, "words": "度(CLcr:20~49mI/min/1.73m2,n=6)肾功能不全对于泊沙康唑的药代动力学不存在显"}, {"probability": {"variance": 0.000202, "average": 0.996382, "min": 0.908626}, "location": {"width": 781, "top": 487, "height": 27, "left": 220}, "words": "著的影响,因此,在轻度至中度肾功能受损患者中,不需要进行剂量调整。在重度肾功能不"}, {"probability": {"variance": 0.009716, "average": 0.959834, "min": 0.535951}, "location": {"width": 781, "top": 526, "height": 27, "left": 220}, "words": "全患者(CIcr:<20mL/min1.73m2)中,平均血浆暴露水平(AUC)与肾功能正常的患者"}, {"probability": {"variance": 0.002605, "average": 0.970794, "min": 0.787797}, "location": {"width": 747, "top": 565, "height": 28, "left": 238}, "words": "CLcr:>80mL/min1.73m2)相似。然而,与其它肾功能受损组(变异系数<40%)相比"}, {"probability": {"variance": 3e-05, "average": 0.996552, "min": 0.974453}, "location": {"width": 783, "top": 604, "height": 28, "left": 220}, "words": "重度肾功能不全患者中,AUC估计值范围存在较高的变异性(变异系数=96%)。由于暴露"}, {"probability": {"variance": 5e-06, "average": 0.998515, "min": 0.989503}, "location": {"width": 715, "top": 645, "height": 26, "left": 221}, "words": "水平存在变异性,必须对重度肾功能受损患者出现的突破性真菌感染进行密切监测"}, {"probability": {"variance": 2e-06, "average": 0.99835, "min": 0.995534}, "location": {"width": 133, "top": 685, "height": 26, "left": 251}, "words": "4、肝功能不全"}, {"probability": {"variance": 0.012246, "average": 0.967426, "min": 0.367958}, "location": {"width": 740, "top": 723, "height": 28, "left": 260}, "words": "在轻度( child-pugh A级,N=6)、中度( Child Pugh B级,N=6)和重度( child-fugli"}, {"probability": {"variance": 0.000945, "average": 0.987533, "min": 0.824041}, "location": {"width": 782, "top": 763, "height": 28, "left": 223}, "words": "C级,N=6)肝功能不全患者中,单次口服泊沙康唑400mg后,平均A与肝功能正常"}, {"probability": {"variance": 0.000511, "average": 0.99216, "min": 0.859579}, "location": {"width": 784, "top": 801, "height": 27, "left": 222}, "words": "的受试者(N=18)相比分别升高43%、27%和21%。与肝功能正常的受试者相比,在轻"}, {"probability": {"variance": 0.002133, "average": 0.982621, "min": 0.729319}, "location": {"width": 784, "top": 835, "height": 34, "left": 221}, "words": "度、中度和重度肝功能不全患者中,平均Cmx分别升高1%、升高40%和降低34%与肝"}, {"probability": {"variance": 0.004339, "average": 0.978242, "min": 0.622923}, "location": {"width": 780, "top": 881, "height": 27, "left": 225}, "words": "功能正常的受试者相比,在轻度、中度和重度肝功能不全患者中,平均表观口服消除率(CL/F"}, {"probability": {"variance": 5.7e-05, "average": 0.99641, "min": 0.961011}, "location": {"width": 782, "top": 921, "height": 26, "left": 223}, "words": "分别下降18%、36%和28%。在肝功能正常的受试者以及轻度、中度和重度肝功能不全患"}, {"probability": {"variance": 0.00425, "average": 0.98128, "min": 0.673026}, "location": {"width": 609, "top": 961, "height": 26, "left": 225}, "words": "者中,消除半衰期(t1n)分别为27小时、39小时、27小时和43小时"}, {"probability": {"variance": 0.003809, "average": 0.980275, "min": 0.641502}, "location": {"width": 741, "top": 998, "height": 30, "left": 264}, "words": "在轻度至重度肝功能不全( child-pugh A、B和C级)患者中,不建议对本品进行剂量"}, {"probability": {"variance": 0.00425, "average": 0.976101, "min": 0.770406}, "location": {"width": 215, "top": 1039, "height": 26, "left": 225}, "words": "调整/见警告和注意事项"}, {"probability": {"variance": 0.002669, "average": 0.963701, "min": 0.874434}, "location": {"width": 72, "top": 1080, "height": 24, "left": 264}, "words": "5、性别"}, {"probability": {"variance": 0.000119, "average": 0.996128, "min": 0.933503}, "location": {"width": 731, "top": 1116, "height": 29, "left": 264}, "words": "在男性和女性中,泊沙康唑的药代动力学相似。不需要根据性别对本品进行剂量调整"}, {"probability": {"variance": 9e-06, "average": 0.99637, "min": 0.992919}, "location": {"width": 70, "top": 1158, "height": 24, "left": 265}, "words": "6、人种"}, {"probability": {"variance": 0.001332, "average": 0.989693, "min": 0.807219}, "location": {"width": 741, "top": 1195, "height": 28, "left": 266}, "words": "泊沙康唑的药代动力学性质不受人种的显著影响。不需要根据人种对本品进行剂量调整"}, {"probability": {"variance": 1e-06, "average": 0.999282, "min": 0.997461}, "location": {"width": 110, "top": 1291, "height": 23, "left": 232}, "words": "【不良反应】"}, {"probability": {"variance": 1.3e-05, "average": 0.998303, "min": 0.984663}, "location": {"width": 334, "top": 1334, "height": 25, "left": 259}, "words": "1、严重不良反应和其他重要不良反应"}, {"probability": {"variance": 1.9e-05, "average": 0.997704, "min": 0.976258}, "location": {"width": 647, "top": 1379, "height": 29, "left": 269}, "words": "下列严重不良反应和其他重要不良反应在本说明书的其他章节进行详细讨论"}, {"probability": {"variance": 0, "average": 0.999839, "min": 0.999612}, "location": {"width": 119, "top": 1425, "height": 24, "left": 265}, "words": "1)过敏反应"}], "language": 3}